Reneuron Group (RENE)

 

RENE Share PerformanceMore

52 week high6.5000 15/07/15
52 week low2.2615 08/12/15
52 week change -1.1250 (-25.71%)
4 week volume48,312,379 04/04/16

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Are Today’s Double-Digit Rises Just The Start For Filtronic Plc, Angle plc And ReNeuron Group Plc?

Shares in Filtronic (LSE:FTC) have soared by over 20% today after it announced a major new contract win. The designer a...

RENE says first patient treated in RP clinical trial

ReNeuron said the first patient has been treated with the company's cell therapy candidate for the blindness-causing diseas...

First Patient Treated in RP Clinical Trial

RNS Number: 0972S ReNeuron Group plc 15 March 2016 15 March 2016 AIM: RENE ReNeuron Group plc ReNeuron announces first patient treated in US Phase I/II clinical trial in blindness-causing disease, retinitis pigmentosa Marks initiation of ReNeuron's clinical development activities in the US ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-...

ReNeuron Relocates to South Wales

RNS Number: 8153P ReNeuron Group plc 23 February 2016 23 February 2016 AIM: RENE ReNeuron Group plc ReNeuron relocates to South Wales Guildford, UK, 23 February 2016: ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that, from 29 February 2016, its headquarters,...

Director Deals - ReNeuron Group PLC (RENE)

Michael Hunt, Financial Director, exercised 5,361,673 shares in the company on the 3rd February 2016 at a price of 1.00p. Th...

Director Deals - ReNeuron Group PLC (RENE)

Michael Hunt, Financial Director, exercised 5,361,673 shares in the company on the 3rd February 2016 at a price of 1.00p. Th...

Director Deals - ReNeuron Group PLC (RENE)

Michael Hunt, Financial Director, exercised 5,361,673 shares in the company on the 3rd February 2016 at a price of 1.00p. Th...

Director's Dealings

RNS Number: 3861P ReNeuron Group plc 17 February 2016 17 February 2016 AIM: RENE ReNeuron Group plc Director's Dealings Guildford, UK, 17 February 2016: ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy development company, announces that on 3 February 2016, Michael Hunt, Chief Financial Officer, instructed ...

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
24/03/2016
ReNeuron has treated the first patient in its US Phase I/II clinical trial with its cell therapy candidate for the blindness-causing disease retinitis pigmentosa (RP). This is a significant step...
edison investment research
ReNeuron Group plc
29/10/2015
With significant financial resources able to support an extensive clinical development programme over the next three to four years, ReNeuron is well-positioned to determine the true value of its cell...
edison investment research
ReNeuron Group plc
23/04/2015
ReNeuron presented two-year follow-up data from the PISCES study in disabled stroke patients, which confirm the potential for long-term benefits from treatment with its CTX neural stem cells....

Latest discussion posts More

  • Re: bit of info - re RP and HK UoC Irvine

    17$m equates to around #14m. Pretty good grant. Lets hope they get good value for money through results. Mindful of course our trials have to be on par or better ...
    30-Apr-2016
    fredd1eboy
  • bit of info - re RP and HK UoC Irvine

    update re Henry Klassen and his retinitis pigmentosa trial http://www.cirm.ca.gov/our-progress/awards/retinal-progenitor-cells-treatment-retinitis-pigmentosa extract - ...
    29-Apr-2016
    mol42
  • We are now a buy for what its worth!

    RENEURON GROUP Last Signal:BUY Last Pattern:BULLISH STOP LOSS Last Close:3.2500 Change:+0.1250 Percent change+4.00% Membership Benefits Watchlist Signal Update Our ...
    29-Apr-2016
    fredd1eboy

Users' HoldingsMore

Users who hold Reneuron Group also hold..
LLOYDS GRP.16%
BP14%
BARCLAYS13%
GLAXOSMITHKLINE12%
ROCKHOPPER11%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE